Nornicotine in smokeless tobacco as a precursor for carcinogen exposure

无烟烟草中的去甲尼古丁是致癌物质暴露的前体

基本信息

  • 批准号:
    9477430
  • 负责人:
  • 金额:
    $ 38.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-05-01 至 2021-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: The tobacco alkaloid nornicotine is a precursor to N'-nitrosonornicotine (NNN), a potent tobacco-specific carcinogen. NNN is believed to play an important role in the induction of esophageal and oral cavity cancers in tobacco users. Nornicotine contributes to NNN exposure in tobacco users in two ways. In addition to being a precursor to NNN formation in tobacco, it may also be nitrosated endogenously. Endogenous nitrosation of nornicotine that is present in tobacco products can occur in the oral cavity, in the stomach, or elsewhere in the body of tobacco users. This is particularly relevant to the use smokeless tobacco products - a form of tobacco that is kept in the oral cavity for prolonged periods of time, creating favorable conditions for nornicotine nitrosation. Given the high carcinogenic potency of NNN and the association of smokeless tobacco use with oral and esophageal cancers, regulation of nornicotine content in smokeless tobacco products is urgently needed. The Food and Drug Administration (FDA) has authority to regulate harmful and potentially harmful tobacco constituents under the Family Smoking Prevention and Tobacco Control Act. The information on the extent of endogenous nitrosation of nornicotine as a function of its content in smokeless products is crucial for the adequate regulation of this tobacco constituent by the FDA. Aims of this proposal are: (1) to determine the variation of nornicotine content in smokeless products currently marketed in the U.S. There is no information on nornicotine content in individual smokeless brands, and the extent of variation among the currently marketed U.S. products is unknown. Aim 1 will address this important gap and will also provide critical information for Aim 2 of this proposal. (2) To investigate the endogenous formation of NNN in smokeless tobacco users. Smokeless tobacco users will be randomized to a tobacco-free herbal snuff containing various amounts of stable isotope-labeled nornicotine added to it. Isotope-labeled urinary total NNN - a biomarker of exposure to NNN - will be measured in these subjects by using liquid chromatography-tandem mass- spectrometry. This methodology will allow for specific identification of urinary total NNN from endogenous nitrosation of nornicotine, versus that resulting from exposure to NNN in tobacco products. The effect of nornicotine reduction on the extent of endogenous NNN formation will be studied by gradually decreasing the amount of isotope-labeled nornicotine added to study snuff. The results of this study will provide extremely important new information on the endogenous formation of the carcinogenic nitrosamine NNN upon exposure to nornicotine from tobacco use. An understanding of this process is absolutely necessary for the adequate regulation of nornicotine in tobacco products with the purpose of minimizing public harm.
描述:烟草生物碱去甲烟碱是N '-亚硝基去甲烟碱(NNN)的前体,NNN是一种有效的烟草特异性致癌物。NNN被认为在烟草使用者的食管癌和口腔癌的诱导中起重要作用。去甲尼古丁以两种方式导致烟草使用者的NNN暴露。除了是烟草中NNN形成的前体之外,它还可以内源性地被亚硝化。烟草制品中存在的去甲烟碱的内源性亚硝化可发生在烟草使用者的口腔、胃或身体其他部位。这与无烟烟草产品的使用特别相关,无烟烟草产品是一种长期保存在口腔中的烟草,为去甲尼古丁亚硝化创造了有利条件。鉴于NNN的高致癌效力以及无烟烟草使用与口腔癌和食道癌的关联,迫切需要对无烟烟草产品中的去甲烟碱含量进行监管。美国食品和药物管理局(FDA)有权根据《家庭吸烟预防和烟草控制法》对有害和潜在有害的烟草成分进行监管。关于去甲尼古丁的内源性亚硝化程度与其在无烟产品中含量的函数关系的信息对于FDA对该烟草成分的充分监管至关重要。本提案的目的是:(1)确定目前在美国销售的无烟产品中去甲尼古丁含量的变化。没有关于个别无烟品牌中去甲尼古丁含量的信息,目前在美国销售的产品之间的变化程度尚不清楚。目标1将解决这一重要差距,并将为本提案的目标2提供关键信息。(2)目的:探讨无烟烟草使用者神经网络的内源性形成。无烟烟草使用者将被随机分配到一种不含烟草的草药鼻烟,其中含有不同数量的稳定同位素标记的去甲尼古丁。同位素标记的尿总NNN -暴露于NNN的生物标志物-将通过使用液相色谱串联质谱法测量这些受试者。该方法将允许特异性鉴别来自去甲烟碱内源性亚硝化的尿总NNN,与暴露于烟草制品中的NNN所产生的尿总NNN。将通过逐渐减少加入研究鼻烟中的同位素标记的去甲烟碱的量来研究去甲烟碱减少对内源性NNN形成程度的影响。这项研究的结果将提供非常重要的新信息,致癌亚硝胺NNN的内源性形成后,暴露于烟草使用的去甲尼古丁。了解这一过程对于充分监管烟草制品中的去甲尼古丁以最大限度地减少公众危害是绝对必要的。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Can the Public Be Educated About Constituents in Smokeless Tobacco? A Three-Wave Randomized Controlled Trial.
可以对公众进行有关无烟烟草成分的教育吗?
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Irina Stepanov其他文献

Irina Stepanov的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Irina Stepanov', 18)}}的其他基金

Core B: Biomarker and Constituent Core
核心 B:生物标志物和核心成分
  • 批准号:
    10246924
  • 财政年份:
    2017
  • 资助金额:
    $ 38.03万
  • 项目类别:
Constituent yields and biomarkers of exposure for tobacco product regulation
烟草产品监管的成分产量和暴露生物标志物
  • 批准号:
    8729472
  • 财政年份:
    2013
  • 资助金额:
    $ 38.03万
  • 项目类别:
Constituent yields and biomarkers of exposure for tobacco product regulation
烟草产品监管的成分产量和暴露生物标志物
  • 批准号:
    8574995
  • 财政年份:
    2013
  • 资助金额:
    $ 38.03万
  • 项目类别:
Constituent yields and biomarkers of exposure for tobacco product regulation
烟草产品监管的成分产量和暴露生物标志物
  • 批准号:
    9121508
  • 财政年份:
    2013
  • 资助金额:
    $ 38.03万
  • 项目类别:
Core B: Biomarker and Constituent Core
核心 B:生物标志物和核心成分
  • 批准号:
    9567953
  • 财政年份:
  • 资助金额:
    $ 38.03万
  • 项目类别:
Core B: Biomarker and Constituent Core
核心 B:生物标志物和核心成分
  • 批准号:
    9358860
  • 财政年份:
  • 资助金额:
    $ 38.03万
  • 项目类别:

相似国自然基金

Iboga alkaloids骨架导向的不对称串联反应构建吖庚环并[4,5-b]吲哚及其在全合成中的应用
  • 批准号:
    21801032
  • 批准年份:
    2018
  • 资助金额:
    26.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigation on naphthylisoquinoline alkaloids as potential antiausterity chemotherapy for pancreatic cancer
萘基异喹啉生物碱作为胰腺癌潜在抗紧缩化疗的研究
  • 批准号:
    23K26797
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
CAREER: Chemoenzymatic Synthesis of Complex Polycyclic Alkaloids Enabled by A-Ketoglutarate Dependent Iron Enzymes
职业:通过 A-酮戊二酸依赖性铁酶实现复杂多环生物碱的化学酶法合成
  • 批准号:
    2338495
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Continuing Grant
Strategy Driven Synthesis of Complex Alkaloids
复杂生物碱的策略驱动合成
  • 批准号:
    2400232
  • 财政年份:
    2024
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Standard Grant
Synthesis of guanidine alkaloids based on palladium catalyzed cyclization-carbonylation reactions.
基于钯催化环化-羰基化反应合成胍生物碱。
  • 批准号:
    23K06034
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation on naphthylisoquinoline alkaloids as potential antiausterity chemotherapy for pancreatic cancer
萘基异喹啉生物碱作为胰腺癌潜在抗紧缩化疗的研究
  • 批准号:
    23H02104
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Anthropogenic change and disease susceptibility in poison frogs: identifying links with diet, skin alkaloids, and the microbiome
毒蛙的人为变化和疾病易感性:确定与饮食、皮肤生物碱和微生物组的联系
  • 批准号:
    2882384
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Studentship
Synthesis of Anticancer Alkaloids on Cancer Cells with Glycosylated Artificial Metalloenzymes
糖基化人工金属酶合成抗癌细胞生物碱
  • 批准号:
    22KJ1525
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Discovery of analgesic diterpenoid alkaloids from medicinal Aconitum plants using a metabolomic approach
使用代谢组学方法从药用乌头植物中发现镇痛二萜生物碱
  • 批准号:
    10629875
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
Excellence in Research: Biosynthetic investigation of manzamine class alkaloids
卓越研究:曼扎明类生物碱的生物合成研究
  • 批准号:
    2302454
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Standard Grant
Transition Metal-Catalyzed Reaction Development Toward the Synthesis of Alkaloids
过渡金属催化生物碱合成反应的进展
  • 批准号:
    2247315
  • 财政年份:
    2023
  • 资助金额:
    $ 38.03万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了